-
Randomized Controlled Trial Multicenter Study Comparative Study
Effect of empirical treatment with moxifloxacin and meropenem vs meropenem on sepsis-related organ dysfunction in patients with severe sepsis: a randomized trial.
- Frank M Brunkhorst, Michael Oppert, Gernot Marx, Frank Bloos, Katrin Ludewig, Christian Putensen, Axel Nierhaus, Ulrich Jaschinski, Andreas Meier-Hellmann, Andreas Weyland, Matthias Gründling, Onnen Moerer, Reimer Riessen, Armin Seibel, Maximilian Ragaller, Markus W Büchler, Stefan John, Friedhelm Bach, Claudia Spies, Lorenz Reill, Harald Fritz, Michael Kiehntopf, Evelyn Kuhnt, Holger Bogatsch, Christoph Engel, Markus Loeffler, Marin H Kollef, Konrad Reinhart, Tobias Welte, and German Study Group Competence Network Sepsis (SepNet).
- Department of Anesthesiology and Intensive Care Medicine, Friedrich-Schiller University, Jena, Germany.
- JAMA. 2012 Jun 13;307(22):2390-9.
ContextEarly appropriate antimicrobial therapy leads to lower mortality rates associated with severe sepsis. The role of empirical combination therapy comprising at least 2 antibiotics of different mechanisms remains controversial.ObjectiveTo compare the effect of moxifloxacin and meropenem with the effect of meropenem alone on sepsis-related organ dysfunction.Design, Setting, And PatientsA randomized, open-label, parallel-group trial of 600 patients who fulfilled criteria for severe sepsis or septic shock (n = 298 for monotherapy and n = 302 for combination therapy). The trial was performed at 44 intensive care units in Germany from October 16, 2007, to March 23, 2010. The number of evaluable patients was 273 in the monotherapy group and 278 in the combination therapy group.InterventionsIntravenous meropenem (1 g every 8 hours) and moxifloxacin (400 mg every 24 hours) or meropenem alone. The intervention was recommended for 7 days and up to a maximum of 14 days after randomization or until discharge from the intensive care unit or death, whichever occurred first.Main Outcome MeasureDegree of organ failure (mean of daily total Sequential Organ Failure Assessment [SOFA] scores over 14 days; score range: 0-24 points with higher scores indicating worse organ failure); secondary outcome: 28-day and 90-day all-cause mortality. Survivors were followed up for 90 days.ResultsAmong 551 evaluable patients, there was no statistically significant difference in mean SOFA score between the meropenem and moxifloxacin group (8.3 points; 95% CI, 7.8-8.8 points) and the meropenem alone group (7.9 points; 95% CI, 7.5-8.4 points) (P = .36). The rates for 28-day and 90-day mortality also were not statistically significantly different. By day 28, there were 66 deaths (23.9%; 95% CI, 19.0%-29.4%) in the combination therapy group compared with 59 deaths (21.9%; 95% CI, 17.1%-27.4%) in the monotherapy group (P = .58). By day 90, there were 96 deaths (35.3%; 95% CI, 29.6%-41.3%) in the combination therapy group compared with 84 deaths (32.1%; 95% CI, 26.5%-38.1%) in the monotherapy group (P = .43).ConclusionAmong adult patients with severe sepsis, treatment with combined meropenem and moxifloxacin compared with meropenem alone did not result in less organ failure.Trial Registrationclinicaltrials.gov Identifier: NCT00534287.
Notes
Knowledge, pearl, summary or comment to share?You can also include formatting, links, images and footnotes in your notes
- Simple formatting can be added to notes, such as
*italics*
,_underline_
or**bold**
. - Superscript can be denoted by
<sup>text</sup>
and subscript<sub>text</sub>
. - Numbered or bulleted lists can be created using either numbered lines
1. 2. 3.
, hyphens-
or asterisks*
. - Links can be included with:
[my link to pubmed](http://pubmed.com)
- Images can be included with:
![alt text](https://bestmedicaljournal.com/study_graph.jpg "Image Title Text")
- For footnotes use
[^1](This is a footnote.)
inline. - Or use an inline reference
[^1]
to refer to a longer footnote elseweher in the document[^1]: This is a long footnote.
.